Novartis reported first-quarter core earnings per share and net sales that fell short of analyst consensus estimates [1].
These results indicate a challenging start to the fiscal year for the pharmaceutical company, though the decision to maintain future guidance suggests leadership believes the downturn is temporary. The disparity between quarterly performance and long-term projections often signals a strategic pivot or expected recovery in product pipelines.
Core earnings per share for the first quarter declined 15% on a constant currency basis, or 13% in U.S. dollars, to $1.99 [1]. This figure missed the consensus estimate by $0.08 [1].
Net sales also saw a decline, dropping one% year-over-year and five% on a constant currency basis to $13.11 billion [1]. This result missed the consensus estimate by $0.37 billion [1].
Despite these misses, Novartis reaffirmed its guidance for the 2026 fiscal year [1]. The company reported that free cash flow 1 was $3 [2].
Company representatives said they did not provide additional commentary on the specific drivers of the Q1 miss in the available reports, but the reaffirmation of FY26 targets serves as a signal of confidence in the company's mid-term trajectory [1].
“Core earnings per share for the first quarter declined 15% on a constant currency basis”
The gap between Novartis's immediate quarterly misses and its steadfast FY26 guidance suggests the company is prioritizing long-term structural growth over short-term volatility. By maintaining its 2026 targets despite a decline in net sales and earnings, Novartis is signaling to investors that current headwinds are transient and that its strategic roadmap remains intact.
